XML 88 R77.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 28, 2025 | Sep. 29, 2024 | Sep. 28, 2025 | Sep. 29, 2024
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | $ 16,654 | $ 17,702 | $ 45,022 | $ 45,864
Alliance revenues |  | 2,298 | 1,900 | 6,684 | 6,140
Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 16,310 | 17,392 | 44,056 | 44,987
Biopharma [Member] | U.S. Commercial Division [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [1] | 10,599 | 11,964 | 27,677 | 29,218
Biopharma [Member] | International Commercial Division [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 5,711 | 5,428 | 16,379 | 15,769
Pfizer CentreOne [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [2] | 344 | 285 | 929 | 820
Pfizer Ignite [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 0 | 25 | 37 | 56
Total Alliance revenues [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Alliance revenues |  | 2,298 | 1,900 | 6,684 | 6,140
Royalty [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Royalty revenue |  | 436 | 384 | 1,170 | 992
Primary Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 7,646 | 9,060 | 18,882 | 21,224
Primary Care [Member] | Eliquis [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [3] | 2,015 | 1,617 | 5,941 | 5,534
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 1,742 | 1,803 | 4,786 | 4,853
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [4] | 1,225 | 2,703 | 2,144 | 4,989
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 1,151 | 1,422 | 2,097 | 1,970
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 412 | 337 | 1,019 | 870
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 279 | 356 | 553 | 557
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 100 | 81 | 272 | 246
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 721 | 742 | 2,071 | 2,204
Specialty Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 4,411 | 4,289 | 12,775 | 12,215
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 1,591 | 1,447 | 4,692 | 3,907
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 313 | 321 | 763 | 818
Specialty Care [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 154 | 156 | 484 | 468
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 173 | 126 | 465 | 382
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 158 | 152 | 457 | 427
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 154 | 169 | 448 | 507
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 128 | 119 | 329 | 358
Specialty Care [Member] | Octagam [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 113 | 221 | 298 | 400
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 73 | 83 | 286 | 357
Specialty Care [Member] | Cresemba [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 83 | 67 | 267 | 213
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 79 | 63 | 206 | 152
Specialty Care [Member] | All other Hospital [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 985 | 1,041 | 2,971 | 3,082
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 407 | 323 | 1,112 | 1,145
Oncology [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 4,253 | 4,043 | 12,399 | 11,549
Oncology [Member] | Ibrance [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 1,057 | 1,087 | 3,083 | 3,272
Oncology [Member] | Xtandi [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [5] | 578 | 561 | 1,602 | 1,474
Oncology [Member] | Padcev [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 464 | 409 | 1,432 | 1,144
Oncology [Member] | Oncology Biosimilars [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [6] | 315 | 285 | 932 | 828
Oncology [Member] | Lorbrena [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 268 | 206 | 741 | 538
Oncology [Member] | Inlyta [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 226 | 247 | 688 | 736
Oncology [Member] | Adcetris [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [7] | 215 | 268 | 687 | 804
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [8] | 202 | 173 | 519 | 437
Oncology [Member] | Bosulif [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 150 | 161 | 450 | 474
Oncology [Member] | Tukysa [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 110 | 124 | 344 | 351
Oncology [Member] | Aromasin [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 114 | 87 | 333 | 257
Oncology [Member] | Orgovyx [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: | [9] | 112 | 57 | 285 | 136
Oncology [Member] | Elrexfio [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 85 | 40 | 230 | 76
Oncology [Member] | Talzenna [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 47 | 36 | 133 | 91
Oncology [Member] | Tivdak [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | 37 | 34 | 115 | 94
Oncology [Member] | All other Oncology [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues: |  | $ 272 | $ 268 | $ 824 | $ 837
[1] | Refer to Note 13A above.
[2] | PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
[3] | Reflects alliance revenues and product revenues.
[4] | The third quarter and first nine months of 2024 included $442 million of revenue recorded in connection with the creation of the U.S. Strategic National Stockpile of 1.0 million treatment courses, which we supplied at no cost to the U.S. government or taxpayers. The first nine months of 2024 also included a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.
[5] | Primarily reflects alliance revenues and royalty revenues.
[6] | Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Retacrit, Zirabev, Trazimera and Nivestym.
[7] | Reflects product revenues and royalty revenues.
[8] | Erbitux® is a registered trademark of ImClone LLC.
[9] | Reflects alliance revenues.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=pfe_U.S.CommercialDivisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=pfe_InternationalCommercialDivisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PfizerIgniteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_PrimaryCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PaxlovidEUALabeledMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ComirnatyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_NurtecODTVyduraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AbrysvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherPrimaryCareProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_SpecialtyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_VyndaqelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SulperazonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InflectraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZaviceftaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_GenotropinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OctagamMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_CresembaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_CibinqoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherHospitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherSpecialtyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_IbranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XtandiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PadcevMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OncologyBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LorbrenaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InlytaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AdcetrisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BraftoviMektoviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TukysaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AromasinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OrgovyxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ElrexfioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TalzennaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TivdakMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |